Below are selected publications that give an overview of current findings, treatments, and research on neurodegenerative disease. The first publication provides a brief history of clinical trial results on frontotemporal dementia, and subsequent articles are organized from newest to oldest release dates.
1. Therapy and clinical trials in frontotemporal dementia: past, present, and future. August 2016. Journal of Neurochemistry. Tsai RM & Boxer AL.
A summary of past clinical trial results and ongoing treatment strategies, efforts for frontotemporal dementia.
2. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. January 2018. Neurology Journals. Rojas JC, Bang J, et al.
A look at how molecules in the CSF can predict disease progression in progressive supranuclear palsy.
3.18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. October 2017. Annals of Neurology. Schonhaut DR, McMillan CT, et al.
A look at how a new type of PET imaging using new tau tracers can help accurately diagnose progressive supranuclear palsy.
4. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. July 2017. The Lancet Neurology. Boxer AL, Yu JT, et al.
A summary of recent advances in progressive supranuclear palsy.
5. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. November 2016. Neurology Journals. Dutt S, Binney RJ, et al.
A detailed look at how brain imaging measures disease progression in progressive supranuclear palsy and corticobasal syndrome over 6 months and 1 year.
6. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. September 2017. Alzheimer's & Dementia Journal. Sha SJ, Miller ZA, et al.
The first clinical trial for carriers of the GRN gene mutation that causes frontotemporal dementia.
7. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. July 2016. Parkinsonism & Related Disorders. Bang J, Lobach IV, et al.
Data from negative clinical trials can still help us. How data from the davunetide AL-108-231 trial helps us predict disease progression.
8. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. July 2014. The Lancet Neurology. Boxer AL, Lang AE, et al.
The largest and first pivotal clinical trial using a potentially disease modifying therapy for progressive supranuclear palsy.
9. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. February 2013. The Lancet Neurology. Boxer AL, Knopman DS, et al.
One of the earliest, large, multi-center, randomized, double-blind, placebo-controlled trial for frontotemporal dementia that changed the ways physicians treat frontotemporal dementia.